Amalgamated Bank reduced its stake in Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 0.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,055 shares of the health services provider’s stock after selling 97 shares during the period. Amalgamated Bank owned about 0.07% of Amedisys worth $4,144,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in the stock. HighTower Advisors LLC boosted its position in Amedisys by 23.2% during the 4th quarter. HighTower Advisors LLC now owns 5,426 shares of the health services provider’s stock worth $869,000 after buying an additional 1,021 shares during the period. Covestor Ltd acquired a new stake in Amedisys during the 4th quarter worth approximately $28,000. Schroder Investment Management Group boosted its position in Amedisys by 937.3% during the 4th quarter. Schroder Investment Management Group now owns 187,883 shares of the health services provider’s stock worth $30,415,000 after buying an additional 169,770 shares during the period. Gotham Asset Management LLC boosted its position in Amedisys by 3.5% during the 4th quarter. Gotham Asset Management LLC now owns 11,168 shares of the health services provider’s stock worth $1,808,000 after buying an additional 381 shares during the period. Finally, Sio Capital Management LLC acquired a new stake in Amedisys during the 4th quarter worth approximately $2,428,000. 93.36% of the stock is currently owned by institutional investors and hedge funds.
Amedisys Stock Performance
Shares of AMED stock opened at $111.00 on Thursday. The firm has a market capitalization of $3.60 billion, a PE ratio of 25.87, a price-to-earnings-growth ratio of 2.90 and a beta of 0.95. The firm has a fifty day simple moving average of $121.75 and a two-hundred day simple moving average of $129.77. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.43. Amedisys, Inc. has a 12 month low of $101.61 and a 12 month high of $188.88.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. UBS Group downgraded shares of Amedisys from a “neutral” rating to a “sell” rating and cut their target price for the stock from $145.00 to $95.00 in a research report on Tuesday, August 2nd. Jefferies Financial Group restated a “buy” rating and issued a $200.00 price target on shares of Amedisys in a research report on Tuesday, June 28th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Amedisys from $210.00 to $175.00 and set a “buy” rating on the stock in a research report on Tuesday, June 21st. Stifel Nicolaus started coverage on shares of Amedisys in a research report on Tuesday, June 28th. They issued a “hold” rating and a $128.00 price target on the stock. Finally, SVB Leerink dropped their price target on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating on the stock in a research report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $156.25.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.